Monte Rosa Therapeutics, Inc. financial data

Symbol
GLUE on Nasdaq
Location
321 Harrison Avenue, Suite 900, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 421 % -28.3%
Debt-to-equity 55.1 % -4.18%
Return On Equity 9.95 %
Return On Assets 6.42 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.8M shares +0.63%
Common Stock, Shares, Outstanding 61.7M shares +0.63%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 82.2M shares +15.4%
Weighted Average Number of Shares Outstanding, Diluted 82.2M shares +15.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 129M USD +17%
General and Administrative Expense 33.7M USD -2.76%
Operating Income (Loss) 15M USD +52.4%
Nonoperating Income (Expense) 13.5M USD +41.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 28.4M USD +63.1%
Income Tax Expense (Benefit) 4.26M USD +781%
Net Income (Loss) Attributable to Parent 24.2M USD +59.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 69.4M USD -36.2%
Cash, Cash Equivalents, and Short-term Investments 291M USD
Assets, Current 299M USD +7.76%
Property, Plant and Equipment, Net 29.1M USD -12.6%
Operating Lease, Right-of-Use Asset 25.7M USD -7.96%
Other Assets, Noncurrent 445K USD +113%
Assets 360M USD +4.5%
Accounts Payable, Current 5.58M USD -13.8%
Employee-related Liabilities, Current 5.13M USD -0.25%
Liabilities, Current 41.9M USD -1.17%
Operating Lease, Liability, Noncurrent 37M USD -9.41%
Liabilities 91.5M USD -23.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.37M USD -26.3%
Retained Earnings (Accumulated Deficit) -404M USD +5.65%
Stockholders' Equity Attributable to Parent 268M USD +19.3%
Liabilities and Equity 360M USD +4.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 61.7M shares +0.63%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 74.4M USD -34.6%
Depreciation 8.34M USD +9.17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 23.5M USD +59.3%
Property, Plant and Equipment, Gross 52.5M USD +6.13%
Operating Lease, Liability, Current 4.09M USD +17.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Preferred Stock, Shares Authorized 10M shares 0%
Amortization of Intangible Assets 615K USD +191%
Share-based Payment Arrangement, Expense 4.89M USD +8.71%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%